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A Randomized Double Blind Placebo Controlled Trial of 
the Effect of Amiodarone Compared to Placebo Before, 
During, and After Electrical Cardioversion for Persistent 
Atrial Fibrillation 
Kevin S. Charmer. Andrew Birchall, Richard P. Steeds, Yorkshire Cardiology 
Collaborative Research Group, Royal Hallamshirs Hospital, Sheffield, United Kingdom 
Background: Cardioversion (DCCV) of persistent atrial fibrillation (AF) to sinus rhythm 
(SR) improves symptoms. exercise tolerance and vsntricular function. The efficacy of 
DCCV is limited by a high relapse rate within 3 months. Prophylactic treatment with ami- 
odarons may increase success but previous randomised studies have lacked a placebo 
control. This was a randomised double blind comparison of oral amiodarone 400mg BD 
for 2 weeks prior to and POOmg OD for 8 weeks following DCCV with placebo. 
Methods: Subjects with persistent AF aged >18 years stable on anticoagulant therapy 
for more than 2 weeks were randomised. Subjects were reviewed at 1, 4, and 8 weeks 
post-DCCV. 
Results: 172 subjects were enrolled but 4 were withdrawn due to protocol violations and 
7 withdrew consent. There were no significant differences in baseline characteristics 
between those on amiodarone (123) and those on placebo (38) -randomization was dis- 
proportionate as this was a powered, intended sub-study of a larger trial. Reversion to 
SR occurred before elective DCCV in 26 out of 123 (21%) subjects on amiodarone but 
none on placebo (p=O.O02). In the remaining 135 subjects, there was no difference in the 
success rate of DCCV (70/97 (72%) amiodarone v 30/38 (79%) placebo). There was no 
difference in the energy required to obtain SR (mean number of shocks: amiodarone 2.3 
+ 1 “placebo 2.5 + I; total energy: amiodarone 296+ 36 J v placebo 381 + 70 J). At 8 
wseks, 33 (35%) patients who were taking amiodarone had first recurrences of AF com- 
pared to 24 (80%) on placebo (pcO.001). There was an increase in the number of sub- 
jects requiring changes in warfarfn dose following the introduction of amiodarone (83 
(67%)) compared with placebo (8 (21%). p<O.OOl)) but no difference in ths number of 
adverse events over the 8 week follow-up period. 
Conclusion : Pre-treatment with amiodarone has the advantage of chemical CV in a sig- 
nificant number of patients without the need for subsequent DCCV under general anes- 
thesia. Pre-treatment does not alter the efficacy of electrical DCCV or the energy 
required for restoration of SR. Amiodarone is more effective than placebo in the preser- 
vation of SR at 8 weeks following successful CV for AF without an increase in complica- 
tions. 
1089-10 Recurrence Rate of Atrial Fibrillation in Patients After 
the First Relapse: A Comparison Between Metoprolol 
CR/XL, Sotalol, and Amiodarone 
Karlheinz Seidl, Margit Vatsr, Monika Rameken, Andreas Brandt, Axe1 Droegemueller, 
Jochen Senges, Hearl Center, Ludwigshafen, Germany 
Between 01197 and 08102, 517 patients (pts) after their first recurrence of atrial fibrillation 
(AF) were treated either with metoprolol CR/XL (M, 47 mg - 190 mg/die), sotalol (S, 160 
mg - 320 mgldie) or amiodarone (A, maintaining dose 200 mgidie) for the first time as 
long-term therapy after successful electrical cardioversion. Follow up was performed in 
all pts for symptomatic recurrence of AF. 
Results: Age (62 * 11 (M) vs 63 f 11 (S) YS 62 t IO (A) years), frequency of male sex 
(72% vs 74% vs 67%). left atrial diameter (44 f 6 vs 44 * 6 vs 45 + 5) and frequency of 
organic heart disease (58% vs 55% YS 62%) were comparable between all groups. Dur- 
ing follow up of 3 years 94/161 (58%) treated with M and 163/228 pts (71%) treated with 
Sand 1271182 pts (70%) treated with A suffered from symptomatic recurrence of AF. In a 
multiple logistic regression model pts treated with M had a significant better outcome 
than pts treated with S or A in maintaining sinus rhythm (OR = 0.6, 95% Cl 0.35 - 0.89, p 
= 0.013), adjusted for age > 70 years, gender, left atrial diameter > 45 mm, organic healt 
disease. Conclusion: During a mean follow up of about 3 years pts treated with M had a 
better outcome than pts with S or A in maintaining sinus rhythm after successful electrical 
cardioversion of AF. About 40% of pts treated with M were free of symptomatic recur- 
rence of AF. Pts treated with M had a higher compliance than pts treated with S or A. 
Metoprolol CW sotalol amiodarone 
XL 
” 161 pts 228 pts 128 pts 
recurrence 94/161 pts 163/228 pts 127/l 62 pts 
(58%) (71%) (70%) 
compliance 92% 85% 76% 
follow up (mean +/-SD, 966 +I- 451 981 +/- 412 889 +/- 436 
days) 
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1089-l 1 Oral Bolus of IC Antiarrhythmic Drugs for Atrial 
Fibrillation: Outpatient Versus Inpatient Administration 
Nassir F. Marrouche, Johannes Brachmann, Jens Guenther, Volker Schibgilla, Walid 
Saliba. GeN Tomassoni, Salwa Beheiw. Ennio Pisano. Dianna Bash, The Cleveland 
Clinic Foundation, Cleveland, OH, Klinikum Coburg, Coburg, Germany 
We prospectively assessed the safety of outpatient versus inpatient administration of a 
large oral dose of either Propafenone (P) or flecainide (F) combined with metoprolol or 
diltiazem. A total of 6O+l mg of P or 300 mg of F were given with 25-50 mg of Metoprolol 
or 240 mg of diltiazem slow release. Patients were randomized to inpatient administra- 
tion under monitored conditions or outpatient administration. A total of 107 patients were 
enrolled in 5 institutions. Fifty-six patients were assigned to inpatient and 61 patients to 
outpatient administration of drugs. 
Termination was achieved in 34 out of 56 (61%) inpatient and in 45 out of the 61 (73%) 
outpatient subjects. None of the patients had syncope. Two patients on F experienced 
near syncope before temlinaiion of AF. Sustained rates faster than 150 bpm were seen 
in 4 patients, all on F. Symptomatic Bradycardia before or after terminatiomof AF was not 
observed. Transient side effects not requiring discontinuation of therapy was reported by 
73 patients (63%). These included metallic taste (45 pts), gastric discomfort (23 pts), diz- 
ziness (3 pts), and tremor (2 pts). Drugs wers discontinued in 1 outpatient, and 1 inpa- 
tient subjects. In 2 outpatients, and 1 inpatient subjects Metoprolol and diltiazem were 
increased to achieve better rate control. 
In conclusion, outpatient initiation of a large oral bolus of IC drug combined with rate con- 
trol drugs appeared as safe as inpatient initiation. 
1089-12 Which Right Atrial Site Is Better for Burst 
Overstimulation of Acute Atrial Fibrillation and Atypical 
Atrial Flutter? 
Nikolav Shlevkov, Alexander Yang. Rainer Schimpf. Helga Bislik, Jan Schrickel, 
Alexander Bitzen. Jiirg 0. Schwab, Berndt Ltidsritz, Thorsten Lewalter, University of 
Bonn, Bonn, Germany 
Aim: To compare prospectively the efficacy of 20-Hz burst pacing at Iwo defined right 
atrial sites with a “no pacing” strategy in the termination of acute atrial fibrillation (AF) or 
atypical atrial flutter (AAFL). Methods: In 76 consecutive patients (pts) (52*14 years, 50 
male) a total of 87 episodes of sustained (r2 min) spontaneous or induced acute AF 
(n=51) or AAFL (n=36) occurred during electrophysiologic study. AF and AAFL were 
defined by polymorphic and monomorphic endowdial activity with cycle lengths ~210 
ms, respectively. The pts were randomised to 3 treatment strategies: (1) pacing at the 
right atrial appendage (RAA) using up to IO consecutive 20-Hz burst trains (duration of 
each train: 3 s. interval between two trains: 15 s) followed bv oacino at the coronaw sinus ,. _ 
ostium (CS-OS) in case of AF/AFFL persistence: (2) pacing at the CS-OS using the same 
oacmo technioue followed bv burst oacino at RAA or 131 observation of AFiAFFL for 6 
Ain. Results: burst pacing a;the C&OS las associate; with a significantly higher AAFL 
conversion rate than both RAA pacing (~~0.03) and the observation strategy (p<O.OOl). 
whereas there was no difference between the 3 strategies in regard to AF termination 
(Figure 1). Conclusion: Burst pacing (20-Hz) at the CS-OS was successful in 85 % of the 
AAFL pts and demonstrated to be significantly superior to RAA-pacing or the observation 
strategy. This finding may be of relevance for pts undergoing implantation of a pace- 
maker capable of atrial burst pacing. 
1089-13 Mechanisms Responsible for the Initiation and 
Maintenance of Atrial Fibrillation Assessed by 
Noncontact Endocardial Mapping System 
Seunq Woon Rha, Young-Hoon Kim, Sang Weon Park, Cheol Ung Choi, Seong Mi Park, 
Wan Joo Shim, Young Moo Ro, Korea University Medical Center. Seoul, South Korea 
Background:.We undertook this study to assess whether a single reentry or focal activ- 
ity is important in the initiation and maintenance of atrial fibrillation (AF) and their relation- 
ship with underlying anatomical struc1ures using a non-contact mapping system in 
patients with AF. 
Method: 20 patients(r6 men, mean age 52, range 25-68 years) with paroxysmal AF 
(n=l8) and persistent AF (n=2) underwent lefl atrial mapping. A multielectrode array 
(Ensite 3000) and a conventional ablation catheter were advanced into the left atrium 
(LA) following double transseptal punctures. Activation sequences of atrial premature 
contraction (APC) which triggered AF or drove AF to maintain were mapped. The relation 
between the activation panern during spontaneous AF or induced AF after internal car- 
dioversion using direct current and underlying anatomical structures were identified. 
Results: During AF. maximal number of wavelets were 3 in 65% (11/17) of patients, and 
2 in 35% (6/17) and the mean number of wavelets was 1.4. 2 different mechanisms 
responsible for the initiation and maintenance of AF were observed: 1) Focally triggered 
